Planned/scheduled da vinci robotic hysterectomy- "(b)(6), scrub tech, informed (b)(4) that dr.(b)(6) injured the patient's vena cava bifurcation during insertion of a laparoscopic camera trocar.(b)(4) spoke to the surgeon directly and was informed that the da vinci surgical system did not cause or contribute to the patient's injury.According to (b)(4), the insertion of the trocar was performed blindly and without direct visualization.Two cardiovascular surgeons repaired the vessel and the patient was closed and taken to the icu." intervention - "vessel repair." patient status - "stable.".
|
No product is being returned for evaluation and no lot # has been provided to manufacturer.A final report will be sent once the results have been analyzed.In accordance to 21 cfr 803.56, if we obtain additional information, which was not known or was not available when the initial report was submitted, then the supplemental report will be submitted to the fda.
|
The event product was not returned for evaluation.It was stated during complaint intake that this unit was not available for investigation.In the absence of the subject device, it is difficult to determine the root cause of the event.The root cause of the event could not be determined as the device was not returned to applied medical for investigation.As stated in the instructions for use (ifu), "potential complications associated with the use of fios first entry are the same as those associated with the use of surgical trocars, insufflation needles, and laparoscopic surgery in general and include, but are not limited to: superficial lesions, injury to internal vessels, bleeding, hematoma, injury to the abdominal wall, infection, peritonitis, and pre-peritoneal insufflation." during the manufacturing process, all trocars are thoroughly inspected for functionality and performance prior to packaging.Applied medical continuously seeks to improve the form, function and ease of use of its products and will continue to monitor its vigilance system for trends and take appropriate actions as necessary.In accordance with 21 cfr 803.56, if additional information is obtained, which was not known or was not available when this report was submitted, then a supplemental report will be submitted to the fda.
|